NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IQV stock has increased by 12.8% and is now trading at $141.52. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings data on Tuesday, April, 28th. The medical research company reported $1.50 EPS for the quarter, topping analysts' consensus estimates of $1.48 by $0.02. The medical research company earned $2.75 billion during the quarter, compared to analyst estimates of $2.74 billion. Iqvia had a return on equity of 18.48% and a net margin of 1.93%. Iqvia's quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $1.53 earnings per share. View Iqvia's earnings history.

Iqvia issued an update on its second quarter earnings guidance on Tuesday, April, 28th. The company provided earnings per share (EPS) guidance of $1.00 to $1.09 for the period, compared to the Thomson Reuters consensus estimate of $1.15. The company issued revenue guidance of $2.365 billion to $2.440 billion, compared to the consensus revenue estimate of $2.47 billion.

15 brokerages have issued 1 year price targets for Iqvia's stock. Their forecasts range from $110.00 to $195.00. On average, they anticipate Iqvia's stock price to reach $153.73 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View analysts' price targets for Iqvia.

Headlines about IQV stock have been trending negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iqvia earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news about Iqvia.

Iqvia saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,600,000 shares, a decline of 5.8% from the June 15th total of 2,760,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the short-interest ratio is currently 1.7 days. Approximately 1.4% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Chipotle Mexican Grill (CMG), Endologix (ELGX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), Paypal (PYPL) and Accenture (ACN).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $141.52.

Iqvia has a market capitalization of $27.02 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]